About us

Palla Pharma Norway (PPN), an independent 100% Norwegian owned pharmaceutical company originally established in 1949 that produces active pharmaceutical ingredients (API) and finished dose formulations (FDF) for a global market.

We see ourselves as a highly adaptable, forward-thinking, and innovative company that has earned a reputation among customers for the high quality of our products and services.

Palla Pharma has developed an innovative, efficient, and environmentally – sustainable extraction and purification manufacturing process for API and are highly experienced when it comes to transforming powder into finished dose formulations.

We have adopted industry best practices across every facet of our operations from procurement to sales. Palla Pharma Norway’s biggest asset is our experienced and highly skilled employees that provides PPN with its greatest advantage.

Organizational chart

  • PALLA PHARMA NORWAY HOLDING AS

    Organisasjonsnummer: 919 610 581
    Navn/foretaksnavn: PALLA PHARMA NORWAY HOLDING AS
    Organisasjonsform: Aksjeselskap
    Forretningsadresse: Gruveveien 1, 3770 KRAGERØ

    • PALLA PHARMA NORWAY AS

      Organisasjonsnummer: 918 275 452
      Navn/foretaksnavn: PALLA PHARMA NORWAY AS
      Organisasjonsform: Aksjeselskap
      Forretningsadresse: Gruveveien 1, 3770 KRAGERØ

    • PALLA PHARMA (UK) HOLDING LIMITED

      Company number: 12500847
      Name: PALLA PHARMA (UK) HOLDING LIMITED
      Company type: Private limited Company
      Contact person: Karin Bjune Sveen
      Correspondence address; Gruveveien 1, 3770 Kragerø Norway

    • PALLA PHARMA EIENDOM AS

      Organisasjonsnummer: 932 458 381
      Navn/foretaksnavn: PALLA PHARMA EIENDOM AS
      Organisasjonsform: Aksjeselskap
      Forretningsadresse: Gruveveien 1, 3770 KRAGERØ

Our Story

Over the Years

1940

Weiders Farmasøytiske

  • Founded by Olaf Weider (Oslo)
1949

Kragerø

  • Established in Kragerø
1954

Painkiller

  • First painkiller introduced
1963

New site

  • New manufacturing site for tablets established and all production moved to Kragerø
1998

Weifa AS

  • Name change to Weifa AS
2014

Sold

  • Sold to Aqualis AS August 2014 and listed on Oslo Stock Exchange as Weifa ASA
2015

Divided

  • Divided into two companies: Weifa / Vistin Pharma.
2017

Sold

  • Sold to TPI Australia. Pitch: From poppy to FDF
2022

Acquired

  • Acquired by Norwegian investors. Acquisition of MA’s

 

2023

Opiat and FDF production